Sage Therapeutics (SAGE) Hits 'Very Significant Milestone' - BMO

BMO Capital analyst Gary Nachman reiterated an Outperform rating and $80 price target on Sage Therapeutics (NASDAQ: SAGE) hit its most important milestone as a company to date with very positive data for Brexanolone in two Phase 3 studies in post-partum depression.

Nachman said the results are "encouraging and enable SAGE to file in the US and Europe, and we see a high probability of approval."

Further, he said the data could potentially bode well for the anticipated SAGE-217 results in both MDD (4Q17) and PPD (1Q18)

For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.

Shares of Sage Therapeutics closed at $62.66 yesterday.

You May Also Be Interested In

• Baldwin Insurance (BWIN) PT Raised to $25 at BMO Capital
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen
• Taysha Gene Therapies (TSHA) PT Raised to $14 at BMO Capital on Differentiation